Drugs / recombinant tissue plasminogen activator
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00894803 | Jul 2009 → Oct 2012 | brain infarction, ischemic stroke | University of Cincinnati | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant tissue plasminogen activator | “Intravenous recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy.” NCT00894803 ↗ |
| Known as | rt-PA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00894803 ↗ |
| Modality | Protein / enzyme biologic | “Intravenous recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy.” NCT00894803 ↗ |
| Route | Intravenous | “Intravenous recombinant tissue plasminogen activator (rt-PA)” NCT00894803 ↗ |